

Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

<https://marketpublishers.com/r/C92B8012DB61EN.html>

Date: November 2023

Pages: 263

Price: US\$ 4,950.00 (Single User License)

ID: C92B8012DB61EN

Abstracts

The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.

“The monoclonal antibodies segment accounted for the largest share by application in 2022.”

In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater

productivity & flexibility and reduce costs.

“The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028.”

The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Thermo Fisher Scientific Inc. (US)

Danaher Corporation (US)

Sartorius AG (Germany)

Thermo Fisher Scientific Inc. (US)

Repligen Corporation (US)

Merck KGaA (Germany)

3M Company (US)

Getinge AB (Sweden)

Eppendorf SE (Germany)

Corning Incorporated (US)

Entegris (US)

FUJIFILM Holdings Corporation (Japan)

Meissner filtration products, Inc. (US)

Kühner AG (Switzerland)

Esco Lifesciences Group (Singapore)

SATAKE MultiMix Corporation (Japan)

Bionet (Spain)

Stobbe Group (Switzerland)

bbi-biotech GmbH (Germany)

OmniBRx Biotechnologies (India)

Cell Culture Company, LLC (US)

Pierre Guérin (France)

Solida Biotech GmbH (Germany)

Zellwerk GmbH (Germany)

3D Biotek, LLC (US)

FiberCell Systems Inc. (US)

Research Coverage:

This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous

bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market

Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), K?hner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SEGMENTATION

FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION

1.4 YEARS CONSIDERED

1.5 CURRENCY CONSIDERED

1.6 LIMITATIONS

1.7 STAKEHOLDERS

1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES

2.2 MARKET SIZE ESTIMATION

FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)

FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)

FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)

2.2.1 INSIGHTS FROM PRIMARIES

FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS

FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

2.3 GROWTH FORECAST

FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023–2028)

FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

2.4 DATA TRIANGULATION & MARKET BREAKDOWN

FIGURE 11 DATA TRIANGULATION METHODOLOGY

2.5 RESEARCH ASSUMPTIONS

2.6 RISK ANALYSIS

2.7 RECESSION IMPACT ANALYSIS

TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)

TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)

TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)

3 EXECUTIVE SUMMARY

FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)

FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)

FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)

FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET

4 PREMIUM INSIGHTS

4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW

FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD

4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022

4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION

FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2 MARKET DYNAMICS

TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS

5.2.1 DRIVERS

- 5.2.1.1 Rising demand for biopharmaceuticals
- 5.2.1.2 Growing adoption among CDMOs and CMOs
- 5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
- 5.2.1.4 Favorable regulatory & government support for innovative technologies
- 5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing

5.2.2 RESTRAINTS

- 5.2.2.1 High capital investments to limit entry for smaller players
- 5.2.2.2 Stringent regulatory requirements

5.2.3 OPPORTUNITIES

- 5.2.3.1 High growth potential of emerging economies
- 5.2.3.2 PAT-enabled optimization of continuous bioprocessing

5.2.4 CHALLENGES

- 5.2.4.1 Integration into existing manufacturing facilities
- 5.2.4.2 Operational challenges

5.3 PRICING ANALYSIS

TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)

TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)

5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS

5.5 VALUE CHAIN ANALYSIS

FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS

- 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
- 5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES

5.6 SUPPLY CHAIN ANALYSIS

FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET

TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM
(SUPPLY/DEMAND SIDE)

5.8 PATENT ANALYSIS

FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING
MARKET (JANUARY 2013–SEPTEMBER 2023)

5.9 KEY CONFERENCES AND EVENTS

TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF
CONFERENCES AND EVENTS (2023?2024)

5.10 REGULATORY LANDSCAPE

5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER
ORGANIZATIONS

TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS

TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS

TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS

5.10.2 REGULATORY GUIDELINES

5.11 PORTER'S FIVE FORCES ANALYSIS

TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER'S FIVE FORCES
ANALYSIS

5.11.1 THREAT OF NEW ENTRANTS

5.11.2 THREAT OF SUBSTITUTES

5.11.3 BARGAINING POWER OF SUPPLIERS

5.11.4 BARGAINING POWER OF BUYERS

5.11.5 INTENSITY OF COMPETITIVE RIVALRY

5.12 TECHNOLOGY ANALYSIS

5.13 KEY STAKEHOLDERS AND BUYING CRITERIA

FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
CONTINUOUS BIOPROCESSING PRODUCTS

5.14 KEY BUYING CRITERIA, BY END USER

FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS
BIOPROCESSING MARKET

6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT

6.1 INTRODUCTION

TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028
(USD MILLION)

6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES

6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE
MARKET

TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY
REGION, 2021–2028 (USD MILLION)

TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND
CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND
CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)

6.3 FILTRATION SYSTEMS AND DEVICES

6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO
DRIVE MARKET

TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028
(USD MILLION)

TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES
MARKET, BY REGION, 2021–2028 (USD MILLION)

6.4 BIOREACTORS

6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND

TABLE 27 BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)

6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS

6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH

TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

6.6 OTHER PRODUCTS

TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)

7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION

7.1 INTRODUCTION

TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

7.2 COMMERCIAL OPERATIONS

7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET

TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

7.3 CLINICAL OPERATIONS

7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET

TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS

8.1 INTRODUCTION

TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

8.2 DOWNSTREAM BIOPROCESS

8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET

TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)

TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)

8.3 UPSTREAM BIOPROCESS

8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH

TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)

TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)

9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION

9.1 INTRODUCTION

TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

9.2 MONOCLONAL ANTIBODIES

9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET

TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

9.3 VACCINES

9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET

TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)

TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)

9.4 CELL & GENE THERAPY

9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND

TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)

9.5 OTHER APPLICATIONS

TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS,

BY REGION, 2021–2028 (USD MILLION)

TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)

10 CONTINUOUS BIOPROCESSING MARKET, BY END USER

10.1 INTRODUCTION

TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET

TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)

10.3 CONTRACT RESEARCH ORGANIZATIONS (CRO) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMO)

10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL &

BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET

TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)

10.4 ACADEMIC & RESEARCH INSTITUTES

10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH

TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)

TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)

11 CONTINUOUS BIOPROCESSING MARKET, BY REGION

11.1 INTRODUCTION

TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028
(USD MILLION)

11.2 NORTH AMERICA

FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET
SNAPSHOT

TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY
PRODUCT, 2021–2028 (USD MILLION)

TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY
SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY
PROCESS, 2021–2028 (USD MILLION)

TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY
APPLICATION, 2021–2028 (USD MILLION)

TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END
USER, 2021–2028 (USD MILLION)

11.2.1 US

11.2.1.1 High biopharmaceutical R&D spending to drive market

TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT,
2021–2028 (USD MILLION)

TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF
OPERATION, 2021–2028 (USD MILLION)

TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS,
2021–2028 (USD MILLION)

TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION,
2021–2028 (USD MILLION)

TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER,
2021–2028 (USD MILLION)

11.2.2 CANADA

11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to
propel market

TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT,
2021–2028 (USD MILLION)

TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF
OPERATION, 2021–2028 (USD MILLION)

TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS,
2021–2028 (USD MILLION)

TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY

APPLICATION, 2021–2028 (USD MILLION)

TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.3 NORTH AMERICA: RECESSION IMPACT

11.3 EUROPE

TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.1 GERMANY

11.3.1.1 Increasing initiatives for life sciences research to boost demand

TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.2 UK

11.3.2.1 Favorable government support for biotech clusters to propel market

TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.3 FRANCE

11.3.3.1 Rising demand for mAbs and biologics to drive market

TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.4 ITALY

11.3.4.1 Growth in pharma & biopharma industries to boost demand

TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.5 SPAIN

11.3.5.1 Increasing R&D funding by academic institutes to support market growth

TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.6 REST OF EUROPE

TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.7 EUROPE: RECESSION IMPACT

11.4 ASIA PACIFIC

FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT

TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.1 CHINA

11.4.1.1 Government support and rising private investments to drive market growth

TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.2 JAPAN

11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support

market growth

TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.3 INDIA

11.4.3.1 Growth in pharmaceutical industry to boost demand

TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.4 SOUTH KOREA

11.4.4.1 Rising focus on quality manufacturing practices to drive market

TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.5 REST OF ASIA PACIFIC

TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY

SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.6 ASIA PACIFIC: RECESSION IMPACT

11.5 LATIN AMERICA

TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.1 BRAZIL

11.5.1.1 Rising focus on cell & therapy manufacturing to support market

TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.2 MEXICO

11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth

TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF

OPERATION, 2021–2028 (USD MILLION)

TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.3 REST OF LATIN AMERICA

TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.4 LATIN AMERICA: RECESSION IMPACT

11.6 MIDDLE EAST & AFRICA

TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.6.1 MIDDLE EAST

11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market

TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY

PROCESS, 2021–2028 (USD MILLION)

TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.6.2 AFRICA

11.6.2.1 Favorable initiatives for R&D investments to support market growth

TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)

TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)

11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.3 REVENUE SHARE ANALYSIS

FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018?2022)

12.4 MARKET SHARE ANALYSIS

FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)

TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY

12.5 COMPANY EVALUATION MATRIX

12.5.1 STARS

12.5.2 PERVASIVE PLAYERS

12.5.3 EMERGING LEADERS

12.5.4 PARTICIPANTS

FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)

12.5.5 COMPANY FOOTPRINT ANALYSIS

TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)

12.5.6 PRODUCT FOOTPRINT OF COMPANIES

TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS

12.5.7 REGIONAL FOOTPRINT OF COMPANIES

TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS

12.6 START-UP/SME EVALUATION MATRIX

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)

12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES

TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS

TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES

12.7 COMPETITIVE SCENARIOS AND TRENDS

12.7.1 PRODUCT LAUNCHES

TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)

12.7.2 DEALS

TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020?OCTOBER 2023)

12.7.3 OTHER DEVELOPMENTS

TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)

13 COMPANY PROFILES

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

13.1 KEY PLAYERS

13.1.1 DANAHER CORPORATION

TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW

FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)

13.1.2 SARTORIUS AG

TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW

FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)

13.1.3 THERMO FISHER SCIENTIFIC INC.

TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW

FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)

13.1.4 REPLIGEN CORPORATION

TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW

FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)

13.1.5 MERCK KGAA

TABLE 249 MERCK KGAA: BUSINESS OVERVIEW

FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)

13.1.6 3M COMPANY

TABLE 250 3M COMPANY: BUSINESS OVERVIEW

FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)

13.1.7 GETINGE AB

TABLE 251 GETINGE AB: BUSINESS OVERVIEW

FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)

13.1.8 EPPENDORF SE

TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW

FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)

13.1.9 CORNING INCORPORATED

TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW

FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)

13.1.10 ENTEGRIS

TABLE 254 ENTEGRIS: BUSINESS OVERVIEW

FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)

13.1.11 FUJIFILM HOLDINGS CORPORATION

TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW

FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)

13.1.12 MEISSNER FILTRATION PRODUCTS, INC.

TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW

13.1.13 K?HNER AG

TABLE 257 K?HNER AG: BUSINESS OVERVIEW

13.1.14 ESCO LIFESCIENCES GROUP

TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW

13.1.15 SATAKE MULTIMIX CORPORATION

TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW

13.2 OTHER PLAYERS

13.2.1 BIONET

13.2.2 STOBBE GROUP

- 13.2.3 BBI-BIOTECH GMBH
- 13.2.4 OMNIBRX BIOTECHNOLOGIES
- 13.2.5 CELL CULTURE COMPANY, LLC
- 13.2.6 PIERRE GU?RIN
- 13.2.7 SOLIDA BIOTECH GMBH
- 13.2.8 ZELLWERK GMBH
- 13.2.9 3D BIOTEK, LLC
- 13.2.10 FIBERCELL SYSTEMS INC.

Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats) might not be captured in case of unlisted companies.

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

I would like to order

Product name: Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/C92B8012DB61EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C92B8012DB61EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970